From the U.S. to the Norway, vociferous debates over the efficacy and safety of Covid-19 vaccines have beset pharmaceutical giants like Pfizer Inc. and AstraZeneca Plc and governments the world over are battling anti-vaccine sentiment. Yet, experts say India never registered significant resistance to inoculations until now. The stakes are particularly high because the South Asian country is racing to inoculate 1.3 billion people across villages and crowded slums while grappling with the world’s second highest number of infections.
“There are many unanswered questions because of the total opaqueness and lack of accountability,” said Dinesh Thakur, a former pharmaceuticalexecutive known for exposing fraud at the Indian drugmaker Ranbaxy Laboratories Ltd. “One thing is abundantly clear: They have successfully now created a significant anti-vaccine movement in India.”
Controversial homegrown vaccine risks derailing India s coronavirus vaccine rollout
chicagotribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chicagotribune.com Daily Mail and Mail on Sunday newspapers.
Controversial homegrown vaccine risks derailing India s rollout - South Florida Sun-Sentinel
sun-sentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sun-sentinel.com Daily Mail and Mail on Sunday newspapers.
What s the debate over India s COVID-19 vaccine?
By
Wednesday Feb 03, 2021
India s domestic vaccine made by Bharat Biotech has been surrounded by controversy
The vaccine was approved for human trials by the Indian government in June last year
When India approved its shot before the completion of final human trials, it fuelled a revolt with many at the frontlines of the pandemic refusing the company’s injection
India has its own vaccine for coronavirus - Covaxin - but majority have shown reluctance in taking the shot.
India s drug regulatory authority
gave the green signal to Bharat Biotech s COVID-19 vaccine for human trials in June last year, making it the first domestic candidate from the country as the number of COVID-19 cases in India crossed 565,000 at the time.